You searched for "tinnitus"
The European TINNET COST Action BM1306
Winfried Schlee describes how a major European funding award is bringing together experts who are committed to collectively developing a better understanding of tinnitus. This work is vital if we are to pioneer effective treatments for the condition in its...In conversation with David Stockdale
David Stockdale is stepping away from the British Tinnitus Association (BTA) after 12 years, during which time the organisation has become transformed. Prof David Baguley met with David in the spring sunshine to reflect on past, present and future of...In conversation with Professor Jos Eggermont
Having known Jos for many years, I jumped at the opportunity to catch up with him for our Nov/Dec 2020 series of tinnitus items. My questions reached him during lockdown, and he was enjoying the chance to get on top...In conversation with David Baguley
A reflective discussion with a scientist-practitioner in tinnitus David Baguley has worked in audiology at Addenbrooke’s Hospital since 1985, becoming the Consultant Clinical Scientist in 1989. In 2006, David received an International Award in Hearing from the American Academy of...Unanswered questions in adult ototoxicity associated with platinum-based chemotherapy
Do the potential side-effects on hearing and tinnitus need to be a ‘necessary evil’ of platinum-based chemotherapy? How strong is our evidence base when offering advice to patients and fellow clinicians? David Baguley and his team from the University of...
Stepwise approach to manage palatal myoclonus successfully
Palatal myoclonic tinnitus (PMT) is a rare condition caused by rhythmic voluntary or involuntary movements of the soft palate, mainly the tensor veli palatini and levator veli palatine muscles. Patients usually present with a ‘clicky’ noise in the ear. Oral...Neuromod closes €10 million financing to accelerate commercialisation
Neuromod, an Irish medical device company specialising in tinnitus, has closed a €10 million equity financing deal in a Series B fundraising expansion to expand the availability of tinnitus treatment device, Lenire. Financing was oversubscribed and led by existing investors...Hyperacusis-related distress and comorbid psychiatric illness
Research suggests that over 50% of patients presenting with hyperacusis also present with some form of psychiatric disorder. With this in mind, Dr Aazh outlines what tools clinicians can use to screen for psychological disorders and what path to take...FDA Approved Lenire Expands Number of US Clinics
Neuromod Devices, the medical technology company that developed tinnitus treatment device, Lenire, has partnered with an additional 24 new US clinics to address the significant demand for the FDA Approved tinnitus treatment device.
